Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT-Identified Oligometastatic Castration-Resistant Prostate Cancer.

Henan Zhang Jacob J Orme Feven AbrahaB J StishVal J LoweFabrice LucienErik J TryggestadMichael S BoldLance C PagliaroC Richard ChooDebra H BrinkmannMatthew J IottBrian J DavisJ Fernando QuevedoWilliam S HarmsenBrian A Costello Geoffrey B JohnsonMark A NathanKenneth R OlivierThomas M PisanskyEugene D KwonHaidong Dong Sean S Park

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

This is the first comprehensive effector T-cell immunophenotype analysis in a phase II trial before and after SABR in CRPC. Results are favorable and support the incorporation of immune-based markers in the design of future randomized trials in patients with oligometastatic CRPC treated with SABR.

Keyphrases

pet ct
phase ii
open label
clinical trial
positron emission tomography
placebo controlled
early stage
phase iii
regulatory t cells
current status
dendritic cells
locally advanced
brain metastases
rectal cancer
type iii